NCT02369029View on ClinicalTrials.gov

BAY1238097, First in Man

PHASE1TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Neoplasms

Interventions

DRUG

BAY 1238097

Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.

Trial Locations (6)

6500

Bellinzona

69120

Heidelberg

77030

Houston

94805

Villejuif

00029

HUS

OX3 7LJ

Oxford

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY